GLP-1 medicines and keyhole surgery compared
| Factor | GLP-1 injections (Wegovy, Mounjaro, Saxenda) | Keyhole surgery (sleeve or bypass) |
|---|---|---|
| Average weight loss | About 15% (semaglutide) to about 20% at highest dose (tirzepatide) in clinical trials | 20% to 40% of total body weight (HSE); up to 25% to 30% sleeve, 30% to 35% bypass |
| If treatment stops | Appetite returns; trial follow-up saw roughly two-thirds of lost weight regained within a year | Permanent anatomical change; small regain after 12 to 18 months is common, most loss holds |
| How you pay in Ireland | Ongoing monthly pharmacy prescriptions year after year (mostly private pay) | One hospital procedure (€6,500 to €10,000 sleeve · €7,500 to €12,600 bypass) plus daily vitamins |
| Main risks & side effects | Nausea, reflux, constipation, gallstones, rare pancreatitis; no anaesthetic | General anaesthetic, surgical leak/clot risk, lifelong vitamin monitoring |

How obesity medicines work under the HSE system
The HSE lists four prescription medicine options that an Irish GP or specialist may prescribe alongside lifestyle changes: liraglutide (Saxenda), semaglutide (Wegovy), naltrexone/bupropion (Mysimba) and orlistat. Public funding is much narrower than prescription licensing:
- Saxenda (liraglutide): the only GLP-1 therapy reimbursed for weight management by the HSE, restricted to patients meeting strict clinical criteria through approved prescribing.
- Ozempic (semaglutide): reimbursed by the HSE for type 2 diabetes only, not for weight management alone.
- Wegovy and Mounjaro (tirzepatide): prescribed privately in Ireland; Mounjaro is not reimbursed by the HSE for weight loss after state pharmacoeconomic review found list-price funding not cost-effective.
Private pharmacy prescriptions qualify for 20% Revenue tax relief up to the Drugs Payment Scheme threshold criteria where applicable, yet several years of private monthly pens add up quickly when measured beside a one-off €6,500 to €10,000 sleeve.
HPRA warning: never buy weight-loss pens online
Ireland's Health Products Regulatory Authority (hpra.ie) has warned the public not to buy Ozempic, Wegovy, Saxenda, Rybelsus or Mounjaro from websites or social media sellers. Over 1,400 units of illegal GLP-1 products were detained entering Ireland in a single year (up from 40 two years earlier), with risks of counterfeit pens, wrong doses and contaminated solutions. Always use a registered Irish doctor's prescription and a registered pharmacy.
When injections and surgery work together
It does not have to be an either-or fight. Bariatric physicians increasingly use GLP-1 medicines for six months before surgery when a very high BMI raises anaesthetic risk, or prescribe them years after a sleeve or bypass if biology nudges hunger and weight upward again.
Questions people ask
Do you regain weight when you stop Mounjaro or Wegovy?
Usually a large share of it. In clinical trial extension data for semaglutide, participants regained roughly two-thirds of the weight they had lost within one year of stopping injections.
Is Mounjaro covered on the Medical Card or Drugs Payment Scheme for weight loss?
No. Under HSE reimbursement rules, Saxenda is the only GLP-1 funded for weight loss (under strict criteria), while Ozempic is funded for type 2 diabetes.
Can I have a gastric sleeve after stopping weight loss injections?
Yes. Many surgical patients tried GLP-1 injections first and stopped because of ongoing monthly cost, side effects or a weight plateau. Tell your anaesthetist if you are still taking one, as GLP-1 medicines slow stomach emptying before anaesthesia.
Which works better at BMI 42 with type 2 diabetes?
Both improve blood sugar and weight, while keyhole surgery (especially gastric bypass or sleeve) produces larger average total weight loss without relying on indefinite monthly injections.
